Savara (NASDAQ:SVRA) executives highlighted recent regulatory and commercial milestones for its lead program, molgramostim inhalation solution (Molbreevi), during a discussion at Oppenheimer’s 36th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results